These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 2904635

  • 1. Serotonergic component of SCH 23390: in vitro and in vivo binding analyses.
    McQuade RD, Ford D, Duffy RA, Chipkin RE, Iorio LC, Barnett A.
    Life Sci; 1988; 43(23):1861-9. PubMed ID: 2904635
    [Abstract] [Full Text] [Related]

  • 2. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors.
    Bischoff S, Heinrich M, Sonntag JM, Krauss J.
    Eur J Pharmacol; 1986 Oct 07; 129(3):367-70. PubMed ID: 3536532
    [Abstract] [Full Text] [Related]

  • 3. Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome.
    Bischoff S, Heinrich M, Krauss J, Sills MA, Williams M, Vassout A.
    J Recept Res; 1988 Oct 07; 8(1-4):107-20. PubMed ID: 3290470
    [Abstract] [Full Text] [Related]

  • 4. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors.
    Kessler RM, Ansari MS, Schmidt DE, de Paulis T, Clanton JA, Innis R, al-Tikriti M, Manning RG, Gillespie D.
    Life Sci; 1991 Oct 07; 49(8):617-28. PubMed ID: 1830917
    [Abstract] [Full Text] [Related]

  • 5. Pharmacology of binding of 3H-SCH-23390 to D-1 dopaminergic receptor sites in rat striatal tissue.
    Faedda G, Kula NS, Baldessarini RJ.
    Biochem Pharmacol; 1989 Feb 01; 38(3):473-80. PubMed ID: 2563653
    [Abstract] [Full Text] [Related]

  • 6. A comparison of the selectivities of SCH 23390 with BW737C89 for D1, D2 and 5-HT2 binding sites both in vitro and in vivo.
    Riddall DR.
    Eur J Pharmacol; 1992 Jan 21; 210(3):279-84. PubMed ID: 1351844
    [Abstract] [Full Text] [Related]

  • 7. Striatal D1- and D2-dopamine receptor sites are separately detectable in vivo.
    Leslie CA, Bennett JP.
    Brain Res; 1987 Jul 07; 415(1):90-7. PubMed ID: 2957025
    [Abstract] [Full Text] [Related]

  • 8. In vivo binding of SCH 39166: a D-1 selective antagonist.
    McQuade RD, Duffy RA, Coffin VL, Chipkin RE, Barnett A.
    J Pharmacol Exp Ther; 1991 Apr 07; 257(1):42-9. PubMed ID: 1826927
    [Abstract] [Full Text] [Related]

  • 9. Characterization of the radioiodinated analogue of SCH 23390: in vitro and in vivo D-1 dopamine receptor binding studies.
    McQuade RD, Chipkin R, Amlaiky N, Caron M, Iorio L, Barnett A.
    Life Sci; 1988 Apr 07; 43(14):1151-60. PubMed ID: 3050344
    [Abstract] [Full Text] [Related]

  • 10. Selective and stereospecific interactions of R-SK & F 38393 with [3H]piflutixol but not [3H]spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390.
    O'Boyle KM, Waddington JL.
    Eur J Pharmacol; 1984 Mar 02; 98(3-4):433-6. PubMed ID: 6144559
    [Abstract] [Full Text] [Related]

  • 11. Characterization of [125I]SCH 23982 binding in human brain: comparison with [3H]SCH 23390.
    Laruelle M, Sidhu A, Casanova MF, Weinberger DR, Kleinman JE.
    Neurosci Lett; 1991 Oct 14; 131(2):273-6. PubMed ID: 1837073
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors.
    Lever JR, Scheffel UA, Stathis M, Musachio JL, Wagner HN.
    Life Sci; 1990 Oct 14; 46(26):1967-76. PubMed ID: 2362552
    [Abstract] [Full Text] [Related]

  • 13. Interaction of flunarizine with dopamine D2 and D1 receptors.
    Ambrosio C, Stefanini E.
    Eur J Pharmacol; 1991 May 17; 197(2-3):221-3. PubMed ID: 1833208
    [Abstract] [Full Text] [Related]

  • 14. [3H]SCH 39166, a new D1-selective radioligand: in vitro and in vivo binding analyses.
    McQuade RD, Duffy RA, Anderson CC, Crosby G, Coffin VL, Chipkin RE, Barnett A.
    J Neurochem; 1991 Dec 17; 57(6):2001-10. PubMed ID: 1834801
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum.
    Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A.
    Life Sci; 1984 Oct 29; 35(18):1885-93. PubMed ID: 6387355
    [Abstract] [Full Text] [Related]

  • 16. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively.
    Urwyler S, Markstein R.
    J Neurochem; 1986 Apr 29; 46(4):1058-67. PubMed ID: 2936868
    [Abstract] [Full Text] [Related]

  • 17. Characterization of binding of 3H-SCH 23390 to dopamine D-1 receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions.
    Hyttel J, Arnt J.
    J Neural Transm; 1987 Apr 29; 68(3-4):171-89. PubMed ID: 2881976
    [Abstract] [Full Text] [Related]

  • 18. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA.
    J Pharmacol Exp Ther; 1987 Jan 29; 240(1):167-76. PubMed ID: 3100767
    [Abstract] [Full Text] [Related]

  • 19. Binding sites for [3H]SCH 23390 in retina: properties and possible relationship to dopamine D1-receptors mediating stimulation of adenylate cyclase.
    Makman MH, Dvorkin B.
    Brain Res; 1986 Dec 29; 387(3):261-70. PubMed ID: 2950967
    [Abstract] [Full Text] [Related]

  • 20. Chronic treatment with antidepressants decreases the number of [3H]SCH 23390 binding sites in the rat striatum and limbic system.
    Klimek V, Nielsen M.
    Eur J Pharmacol; 1987 Jul 09; 139(2):163-9. PubMed ID: 3308491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.